0728. Removal of natural anti-galactose α1,3 galactose antibodies with GAS914 enhances humoral immunity and prevents sepsis mortality in mice

Introduction Increasing numbers of patients with immunodeficiencies, malignant diseases, advanced surgeries and prolonged stays in intensive care units are at risk for developing infections by enteric bacteria, which often are systemic (sepsis) and caused by multidrug resistance isolates. Intestinal bacteria provide also a constant antigenic stimulation for the synthesis of natural anti-carbohydrate antibodies such as those targeting blood group-associated antigens or galactose a1,3 galactose (Gal). Enteric bacteria that cause sepsis are more likely to bind anti-Gal antibodies than those isolated from stools, which appears related to the higher resistance to serum killing evidenced by the former microorganisms.